1.39
-0.03(-2.11%)
Currency In USD
| Previous Close | 1.42 |
| Open | 1.39 |
| Day High | 1.48 |
| Day Low | 1.37 |
| 52-Week High | 2.55 |
| 52-Week Low | 0.58 |
| Volume | 48,490 |
| Average Volume | 358,435 |
| Market Cap | 1.31M |
| PE | -1.62 |
| EPS | -0.86 |
| Moving Average 50 Days | 1.88 |
| Moving Average 200 Days | 1.53 |
| Change | -0.03 |
If you invested $1000 in Chemomab Therapeutics Ltd. (CMMB) since IPO date, it would be worth $8.04 as of March 14, 2025 at a share price of $1.39. Whereas If you bought $1000 worth of Chemomab Therapeutics Ltd. (CMMB) shares 5 years ago, it would be worth $133.27 as of March 14, 2025 at a share price of $1.39.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
GlobeNewswire Inc.
Mar 06, 2025 1:00 PM GMT
Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis TEL AVIV, Israel, March 06, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical stage biotechnol
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
GlobeNewswire Inc.
Feb 19, 2025 12:00 PM GMT
Single Positive Phase 3 Trial Designed to Support Full Regulatory Approval, For the First Time Providing Regulatory Clarity in PSC and Positioning Nebokitug to Potentially Become the First FDA-Approved Treatment for PSC No Liver Biopsies or Additiona
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 03, 2025 12:00 PM GMT
TEL AVIV, Israel, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announce